Daptomycin (Ly-146032, Cidecin, Cubicin)

Daptomycin is a member of the Antibiotic A 21978 complex of high molecular weight cyclic lipopeptides with potent antibiotic activity, notably against MRSA, VISA and VRSA resistant bacteria. Originally isolated from Streptomyces roseosprous by Eli Lily in the 1980s, daptomycin was selected and developed by Cubist Pharmaceticals for human use. Daptomycin exhibits Ca-dependent depolarisation of the bacterial membrane resulting in loss of membrane potential leading to inhibition of DNA, RNA and protein synthesis which results in cell death.\n\nSolubility: \nWater, Methanol\n\nImpurities: (same/less than)2.0%\n\nResidue of Ignition: (same/less than)0.1%\n\nWater: (same/less than)2.0%\n\nHeavy Metals: (same/less than)0.002%\n\nStorage and Stability:\nMay be stored at RT for short-term only. Long-term storage is recommended at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

D1066

Size

100mg

Form

Supplied as an off-white to pale yellow powder.\n

Purity

~90%

References

1. Role of branched chain fatty acid precursors in regulation factor profile in the biosynthesis of A21978 C complex. Zmijewski M. J. et al., J. Antibiotics 1986, 39, 1483. 2. Complex of new acidic peptide antibiotics. Isolation, chemistry, and mass spectral structure elucidation. Debono M. et al., J. Antibiotics 1987, 40, 761. 3. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram positive infections. Steenbergen \nJ.N. et al., J. Antimicrobial Chemotherapy 2005, 55, 283.

Alternative Names

Ly-146032; Cidecin; Cubicin;